Showing 1681-1690 of 5063 results for "".
- BullDog Skincare for Men Unveils New Eco-Friendly Packaging, Razorhttps://practicaldermatology.com/news/bulldog-skincare-for-men-unveils-new-eco-friendly-packaging-razor/2460021/With sweet new packaging and a bamboo razor, Bulldog Skincare For Men is once again raising the bar in men’s skincare. The always vegan-friendly and anti-animal testing brand is now dramatically reducing its carbon footprint by using Braz
- Crown Labs Adds to Portfolio with Acquisition of Keri from GSKhttps://practicaldermatology.com/news/crown-labs-adds-to-portfolio-with-acquisition-of-keri-from-gsk/2460017/Crown Laboratories, Inc. acquired the North American rights for Keri from GlaxoSmithKline (GSK). The acquisition of Keri from GSK marks the sixth product from GSK that Crown has acquired in the past five months. “Acqui
- Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for NMSC Patients Treated with Superficial Radiation Therapyhttps://practicaldermatology.com/news/five-year-retrospective-study-shows-989-percent-cure-rate-for-nmsc-patients-treated-with-superficial-radiation-therapy/2460013/Sensus Healthcare, Inc. shared topline results from a five-year retrospective study of non-melanoma ski
- Maine Gets SUNucatedhttps://practicaldermatology.com/news/maine-gets-sunucated/2460001/Maine is joining 19 other states in allowing students to possess and use sunscreen in school. Governor Janet Mills signed LD 441, which was sponsored by Senator Cathy Breen. Modeled after American Society for Dermatologic Surgery Association’s (ASDSA) SUNucate legislation, the bil
- Allergan 360° Aesthetics Report Shines Light on Evolving Beauty Perceptions Around the Worldhttps://practicaldermatology.com/news/allergan-3600-aesthetics-report-shines-light-on-evolving-beauty-perceptions-around-the-world/2459994/The digital boom and millennials are growing the aesthetics category, and wellness and self-care are the new key drivers, according to the Allergan 360° Aesthetics Report. To develop the report, Allergan tapped into more than 14,500
- PALLAS Ti: Sapphire Solid State Laser Shows Similar Efficacy and Safety to 308nm Excimer Laser for Localized Vitiligohttps://practicaldermatology.com/news/pallas-tisapphire-solid-state-laser-shows-similar-efficacy-and-safety-to-308nm-excimer-laser-for-localized-vitiligo/2459953/A novel 311nm Titanium:Sapphire UV laser demonstrates comparable efficacy and safety when compared to 308nm excimer laser in the treatment of localized vitiligo, according to a study recently published in Lasers in Surgery and Medicine. Manufactured by
- BTL to Launch Small Emsculpt Applicator for Arms, Thighs, Calveshttps://practicaldermatology.com/news/btl-to-launch-small-emsculpt-applicator-for-arms-thighs-calves/2459955/BTL is rolling out a small Emsculpt applicator to treat arms, thighs and calves at the annual meeting of the American Society for Laser Medicine and Surgery in Denver. Until now, there were only protocols for the abdominals and buttocks. In addition to launching the small appl
- Allergan Acquires Envy Medical, Inc.https://practicaldermatology.com/news/allergan-acquires-envy-medical-inc/2459957/Allergan now owns Envy Medical, Inc. The acquisition adds Envy's Dermalinfusion, a non-surgical, non-invasive skin resurfacing system for the face and body, to Allergan's portfolio. Offered in physician's offices, medical spas and l
- Constellation Alpha Capital Corp. Signs Letter of Intent to Acquire DermTech, Inc.https://practicaldermatology.com/news/constellation-alpha-capital-corp-signs-letter-of-intent-to-acquire-dermtech-inc/2459970/Constellation Alpha Capital Corp., a special purpose acquisition company, has executed a non-binding Letter of Intent to merge with DermTech, Inc., a molecular genomics company with an initial focus on skin cancer. DermTech markets and develops products that facilitate the early detection of skin
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription